Mitigating the Risk of Cytomegalovirus Infection in the Transplantation Set...

Event Information

Share this event

Date and Time



Marriott Marquis Washington, DC

901 Massachusetts Ave NW

Liberty Salons IJKL; Meeting Level 4

Washington, DC 20001

View Map

Event description


This program is intended for IDWeek™ 2019 attendees only.

Activity Chair

Francisco M. Marty, MD, FIDSA
Associate Professor of Medicine
Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Staff Physician, Dana-Farber Cancer Institute
Boston, MA


Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Kathleen M. Mullane, DO, PharmD, FIDSA, FAST
University of Chicago
Professor, Department of Medicine
Section of Infectious Diseases
Director of Infectious Disease Clinical Trials
Immunocompromised Host Service
Chicago, IL


Cytomegalovirus (CMV) is a common herpesvirus that affects 50% to 80% of the US population. Disease from reactivation of CMV infection in a seropositive individual rarely occurs unless the immune system is suppressed due to either illness or drug therapies—a pivotal concern in patients receiving immunosuppressive therapy following hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). Cytomegalovirus is the most important infectious agent following SOT and is a leading cause of illness in patients who have undergone allogeneic HSCT. In this educational activity, expert physicians will examine the evidence behind CMV preemptive and prophylactic measures for transplant recipients as well as the use of conventional and emerging agents in prevention of CMV infection.


6:00 PM
Registration and Dinner

6:30 PM
Introduction and Pretest
Francisco M. Marty, MD, FIDSA

6:40 PM
Risk Mitigation – Use of Prophylaxis and Preemptive Therapy in CMV Management
Kathleen M. Mullane, DO, PharmD, FIDSA, FAST

7:00 PM
The Emerging Science Behind CMV Prophylaxis
Roy F. Chemaly, MD, MPH, FIDSA, FACP

7:25 PM
Game On!
With your host, Francisco M. Marty, MD, FIDSA

7:45 PM

7:50 PM
Question and Answer

8:00 PM

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Apply the evidence regarding the use of prophylactic and preemptive measures to prevent CMV disease in transplant recipients.

  • Assess the latest clinical evidence regarding antivirals and vaccines for use as prophylactic or preemptive anti-CMV therapy in transplant recipients.

  • Evaluate the safety and resistance profiles of conventional and emerging therapies used to treat or prevent CMV infection.

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with CMV.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Merck & Co., Inc.

This activity is not affiliated with the official program of IDWeek™ 2019.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

Share with friends

Date and Time


Marriott Marquis Washington, DC

901 Massachusetts Ave NW

Liberty Salons IJKL; Meeting Level 4

Washington, DC 20001

View Map

Save This Event

Event Saved